首页|热毒宁注射液联合阿奇霉素对小儿肺炎支原体肺炎的疗效

热毒宁注射液联合阿奇霉素对小儿肺炎支原体肺炎的疗效

扫码查看
目的 探讨热毒宁注射液联合阿奇霉素(AZM)治疗小儿肺炎支原体肺炎(MPP)的疗效与对血清Toll样受体2(TLR2)、肿瘤坏死因子α诱导蛋白8样分子2(TIPE2)、可溶性程序性死亡受体1(sPD-1)的影响.方法 通过随机数字表法将2020年10月至2023年8月南京同仁医院收治的82例小儿MPP患儿分为对照组与试验组,各41例.对照组予以AZM治疗,试验组予以热毒宁注射液联合AZM治疗,以7 d为1个疗程,两组均治疗及随访至出院.比较两组治疗效果,康复情况,治疗前后血清TLR2、TIPE2、sPD-1水平,以及住院期间不良反应发生情况.结果 与对照组治疗后的总有效率(75.61%)比较,试验组总有效率(95.12%)更高(χ2=6.248,P<0.05).试验组发热持续时间、住院时间、咳嗽持续时间分别为(4.76±0.51)d、(9.78±0.95)d、(7.03±0.67)d,短于对照组的(7.22±0.76)d、(12.95±0.82)d、(8.89±0.72)d(t=17.210、16.174、12.109,均P<0.05).试验组TIPE2水平分别为(57.70±5.91)pg·mL-1,高于对照组的(42.63±4.23)pg·mL-1(t=13.277,P<0.05);试验组全血CD8+水平,血清TLR2、sPD-1水平分别为(24.76±1.52)%、(4.46±0.89)ng·mL-1、(141.65±26.40)μg·L-1,低于对照组的(27.25±1.15)%、(7.03±1.34)ng·mL-1、(176.73±38.35)μg·L-1(t=8.365、10.230、4.825,均P<0.05).两组住院期间不良反应发生率比较,差异无统计学意义(19.51%vs 12.20%,χ2=0.823,P>0.05).结论 热毒宁注射液联合AZM应用于小儿MPP的效果较好,可促进其康复,调节机体TLR2、TIPE2、sPD-1表达水平,安全性高.
Therapeutic effect of Reduning injection combined with azithromycin on pneumonia in children caused by mycoplasma pneumoniae
Objective To investigate the efficacy of Reduning injection combined with azithromycin(AZM)in the treatment of mycoplasma pneumoniae pneumonia(MPP)in children and its effects on serum toll-like receptor 2(TLR2),tumor necrosis factor α-induced protein-8-like molecule 2(TIPE2),soluble programmed death receptor 1(sPD-1)and immune function.Methods A total of 82 children with MPP admitted to Nanjing Tongren Hospital from October 2020 to August 2023 were divided into the control group and the experimental group by the random number table method.The patients in the control group were treated with AZM and those in the experimental group with Reduning injection combined with AZM.One course of treatment lasted for 7 days and the patients in both groups were treated and followed up until discharge.The therapeutic efficacy,recovery status,serum levels of TLR2,TIPE2 and sPD-1 before and after treatment,and the occurrence of adverse reactions during hospitalization were compared between the two groups.Results After treatment,the total effective rate was significantly higher in the experimental group than in the control(75.61%vs 95.12%,χ2=6.248,P<0.05).The duration of fever,hospitalization,cough in the experimental group were(4.76±0.51)d,(9.78±0.95)d,(7.03±0.67)d,which were shorter than those of(7.22±0.76)d,(12.95±0.82)d,(8.89±0.72)d in the control(t=17.210,16.174,12.109,all P<0.05).After treatment,TIPE2 level in the experimental group was(57.70±5.91) pg·mL-1,which was higher than that of(42.63±4.23) pg·mL-1 in the control(t=13.277,P<0.05).The serum levels of CD8+,TLR2,sPD-1 in the experimental group were(24.76±1.52)%,(4.46±0.89) ng·mL-1 and(141.65±26.40) μg·L-1,which were lower than those of(27.2±1.15)%,(7.03±1.34) ng·mL-1,(176.73±38.35) μg·L-1 in the control(t=8.365,10.230,4.825,all P<0.05).The incidence of adverse reactions during hospitalization was not statistically different between the two groups(19.51%vs 12.20%,χ2=0.823,P>0.05).Conclusion Reduning injection combined with AZM has good therapeutic effect on MPP in children since it can promote their recovery and regulate the expression levels of TLR2,TIPE2 and sPD-1 in the body.Meanwhile,it is of high safety.

Mycoplasma pneumoniae pneumoniaChildReduning injectionToll-like receptor 2Safety

刘爽、吴佳妮、马杰

展开 >

南京同仁医院儿科,南京 211100

宜兴市中医医院儿科,宜兴 214200

肺炎支原体肺炎 小儿 热毒宁注射液 Toll样受体2 安全性

宜兴市科技项目

2021SF21

2024

中国药物应用与监测
中国人民解放军总医院

中国药物应用与监测

CSTPCD
影响因子:1.983
ISSN:1672-8157
年,卷(期):2024.21(5)